AVSR yields 1000000.00% · ABBV yields 3.09%● Live data
📍 AVSR pulled ahead of the other in Year 1
Combined, AVSR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AVSR + ABBV for your $10,000?
Avistar Communications Corporation designs, develops, manufactures, markets, and sells networked video communications products primarily in the United States, western Europe, and Asia. It delivers a suite of video, audio, and collaboration solutions that are designed to support users in the office through the conference room or on-the-go. The company offers Avistar C3, a communication and collaboration platform, which provides an integrated suite of video, audio, and collaboration applications that include on-demand access to interactive video calling and conferencing, content creation and publishing, broadcast origination and video distribution, and video-on-demand, as well as data sharing, presence-based directory services, and network management. Avistar Communications Corporation also provides various services for the implementation and support of its video communications products; and offers software development, maintenance, support, and training services. In addition, it is involved in the development, prosecution, maintenance, support, and licensing of the intellectual property and technology used in the company's video communications systems. Further, the company sells and licenses a set of desktop products and infrastructure products that combine to form an Avistar video-enabled visual communication and collaboration solution. Avistar Communications Corporation offers its products and services through its direct sales force, as well as through strategic partners and value added resellers. The company was formerly known as Avistar Systems Corporation and changed its name to Avistar Communications Corporation in April 2000. Avistar Communications Corporation was founded in 1993 and is headquartered in San Mateo, California.
Full AVSR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.